EyePoint (EYPT) EBITDA Margin (2010 - 2026)
EyePoint (EYPT) posted EBITDA Margin of 12532.47% for Q1 2026, down 10.46% sequentially from 11345.97% in Q4 2025, and down 1233275.0% YoY from N/an in Q1 2025.
EyePoint (EYPT) EBITDA Margin (2010 - 2026) Analysis & Trends
EyePoint has reported EBITDA Margin for 17 years, with the latest figure at 12532.47% in Q1 2026.
- Quarterly EBITDA Margin fell 1233275.0% year-over-year to 12532.47% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3700.89% (down 341295.0% YoY) and the FY2025 annual result came in at 775.98%, down 43893.0% from the prior year.
- EBITDA Margin retreated to 12532.47% in Q1 2026 per EYPT's latest filing, from 11345.97% in the prior quarter.
- Over five years, EBITDA Margin peaked at 94.71% in Q3 2023 and troughed at 12532.47% in Q1 2026.
- A 5-year average of 2042.4% and a median of 285.18% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2023 and 2026: EBITDA Margin jumped 29864 bps in 2023, then sank 1233275 bps in 2026.
- Over 5 years, EBITDA Margin stood at 415.22% in 2022, then jumped by 72 bps to 116.58% in 2023, then sank by 235 bps to 390.4% in 2024, then tumbled by 2806 bps to 11345.97% in 2025, then slipped by 10 bps to 12532.47% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 12532.47%, 11345.97%, and 6420.81% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | -19,207.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19,207.10% |
| Mar 31, 2026 | -12,532.47% |
| Dec 31, 2025 | -11,345.97% |
| Sep 30, 2025 | -6,420.81% |
| Jun 30, 2025 | -1,166.83% |
| Mar 31, 2025 | -199.72% |
| Dec 31, 2024 | -390.40% |
| Sep 30, 2024 | -311.17% |
| Jun 30, 2024 | -364.52% |
| Mar 31, 2024 | -285.18% |
| Dec 31, 2023 | -116.58% |
| Sep 30, 2023 | -94.71% |
| Jun 30, 2023 | -249.98% |
| Mar 31, 2023 | -280.54% |
| Dec 31, 2022 | -415.22% |
| Sep 30, 2022 | -183.76% |
| Jun 30, 2022 | -166.16% |
| Mar 31, 2022 | -196.73% |
| Dec 31, 2021 | -156.36% |
| Sep 30, 2021 | -169.04% |